Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Introduction
  • Published:

Introduction: centrally acting agents in male sexual dysfunction

International Journal of Impotence Research volume 20, pages S1–S2 (2008)Cite this article

This supplement delves into central nervous system (CNS) aspects of male sexual dysfunction. Our understanding of the role of the CNS in potentiating sexual behavior is progressing rapidly. However, we are still in the early phases of research to determine if CNS-acting agents can be used to help treat various types of sexual dysfunction.

The history of sex therapy is as old as the recorded history of humans. In Mesopotamia, men and women prayed to the goddess Ishtar for virility, fertility and sexual power. Ancient Egyptians were probably not the first to develop potions as aphrodisiacs, but they were among the first to record the formulas for future generations to study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Masters WH, Johnson VE . Human Sexual Inadequacy. Little Brown: Boston, 1970.

    Google Scholar 

  2. Heiman JR, Meston CM . Empirically validated treatment for sexual dysfunction. In: Rosen R, Davis C, Ruppel H (eds). Annual Review of Sex Research. The Society for the Scientific Study of Sexuality: Mount Vernon, IA, 1998, pp259–303.

    Google Scholar 

  3. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA et al. Oral sildenafil in the treatment of erectile dysfunction. N Eng J Med 1998; 338: 1397–1404.

    Article  CAS  Google Scholar 

  4. Ayta IA, McKinley JB, Krane RJ . The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50–56.

    Article  CAS  PubMed  Google Scholar 

  5. Lue T, Guiliano F, Montorsi F, Rosen RC, Andersson KE, Altof S et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6–23.

    Article  PubMed  Google Scholar 

  6. Giuliano F, Rampin O . Neural control of erection. Physiol Behav 2004; 83: 189–201.

    Article  CAS  PubMed  Google Scholar 

  7. Broderick GA . Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. Rev Urol 2003; 5 (Suppl 7): S9–S20.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from Palatin Technologies, Inc. Editorial support for the development of this paper was provided by Kevin Kehres.

Author information

Authors and Affiliations

  1. Tulane University Medical Center, New Orleans, LA, USA

    W J G Hellstrom

Authors
  1. W J G Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W J G Hellstrom.

Additional information

Disclosure

Dr Hellstrom serves as a consultant/advisor, lecturer and/or clinical trial investigator for the following: VIVUS, Mentor, Bayer, Pfizer, Johnson & Johnson, Auxilium, King, Palatin, American Medical Systems, Medtronic, GlaxoSmithKline, Coloplast and Sanofi-Synthelabo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hellstrom, W. Introduction: centrally acting agents in male sexual dysfunction. Int J Impot Res 20 (Suppl 1), S1–S2 (2008). https://doi.org/10.1038/ijir.2008.15

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.15

Search

Advanced search

Quick links